Iptacopan

In the Phase IIIB APPULSE-PNH study, oral Fabhalta® (iptacopan) improved average hemoglobin levels in adult PNH patients switched from anti-C5 therapies. PNH is a rare, chronic blood disorder often treated with anti-C5 therapies, and Fabhalta has shown efficacy and safety in previous Phase III trials. Novartis announced positive results from APPULSE-PNH, with Fabhalta's safety profile consistent with prior data.

In the Phase IIIB APPULSE-PNH study, oral Fabhalta® (iptacopan) improved average hemoglobin levels in adults with paroxysmal nocturnal hemoglobinuria (PNH) switched from anti-C5 therapies.

FDA approves Phase II trial for Ruxoprubart, a selective alternative pathway inhibitor, in IgAN patients, with potential to treat multiple disorders. Ruxoprubart's unique mechanism avoids blocking the classical pathway, offering advantages over existing treatments.

FDA clears Ruxoprubart for Phase II IgAN trial, a selective AP inhibitor with potential in multiple diseases, including PNH, C3G, aHUS, AAV, and IgAN, offering a safer alternative to existing complement blockers.

Novartis presents over 65 abstracts at ASH and SABCS, highlighting new data on Scemblix, Kisqali, and other treatments, emphasizing commitment to cancer and blood disorder patients. The company also showcases personal breast cancer stories at SABCS, aiming to uplift and unite the community.

Novartis to present over 65 abstracts at ASH and SABCS, including 96-week Scemblix results and Kisqali 4-year analysis. Data highlights commitment to cancer and blood disorder treatments.